🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This recent article from the The New York Times highlights the growing importance of #genetictesting in cancer prevention, particularly for those with a family history of cancer. This is a powerful reminder that emphasizes how critical it is to identify risk early, allowing for more

Join a panel of leading #mentalhealth experts for a discussion and Q&A on how the GeneSight® test leads the way in mental health PGx. Don't miss the opportunity to enhance your understanding and stay ahead in the field! 🚨 Save your spot today: brnw.ch/21wSake

We are so excited to return to ACOG's Annual Clinical & Scientific Meeting in #Minneapolis from May 16th - 18th! Make sure to stop by booth # 1921 to meet our team and learn about our latest genetic innovations. See you there! #ACOG2025 #events

Today, we announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). 👉Read more:

Today, we announced we will hold our first quarter 2025 earnings conference call at 4:30 PM EDT on Tuesday, May 6, 2025. 👉 Read more: investor.myriad.com/news-releases/…

Today, we announced that nearly nine out of ten (89%) Americans diagnosed with depression and/or #anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from

Lisa received an elevated MyRisk® with RiskScore® result, leading her provider to schedule tests - ultimately resulting in a cancer diagnosis. Uncovering #breastcancer risk can be key in detecting cancer early. Learn about breast cancer risk assessment: myriad.com/getmyrisk/.

📣 There are just 2 weeks until this year's ACOG Annual Clinical & Scientific Meeting in #Minneapolis! Here's what's in store: 📊 We'll be sharing three groundbreaking abstracts on FirstGene, our industry-leading 8-week prenatal screen, and maternal malignancies. 🧬 Make sure

We're thrilled to present 6 groundbreaking abstracts at the upcoming BRCA Symposium in Montreal, May 6-9! 🎤 Join us as we'll be highlighting our industry-leading innovations in hereditary cancer testing and polygenic risk scores. #hereditarycancer #BRCA2025 #genetictesting

The GeneSight team is excited to head to sunny LA later this month for 4 days of conversation and connection at the American Psychiatric Association (American Psychiatric Association) 2025 Annual Meeting. ☀️ Stop by booth # 1400 to learn how GeneSight can tell you what your patients can't. See

Today, we announced financial results for our first quarter ended March 31, 2025 and updated our previously issued financial guidance on business performance for the full-year 2025. 👉 Read more: investor.myriad.com/news-releases/…

Last week, we released the latest GeneSight Mental Health Monitor, which found that 52% of Americans with depression or anxiety avoid taking mental health medication due to concerns about potential side effects—even though 89% believe they are somewhat or very effective. 54% say

The ACOG Annual Clinical & Scientific Meeting is underway! Head over to booth # 1921 to meet #teamMyriad and learn how we can elevate your practice with advanced genetic and genomic testing solutions for every stage of your patients' healthcare journey. #ACOG2025

We're proud to share Brian Donnelly, Myriad's Chief Commercial Officer, has been named to the 2025 Forbes Entrepreneurial CMO 50 List! 👏 This prestigious recognition honors leaders who are redefining the role of today's commercial executive. Learn more: forbes.com/sites/sethmatl…

Thank you to all of #teamMyriad who participated in this month's NAMI Walks across the US! Last Saturday, teammates in #SLC helped amplify visibility around Mental Health Awareness Month while highlighting the important impact of NAMI in the community. We are proud to

Today, we announced we will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. 👉 Read more: investor.myriad.com/news-releases/…

🌸 Today is Women's Health Day - but at Myriad, supporting women's health is a commitment we uphold each day. Our Women's Health team empowers patients & providers with actionable information to support people & families on their healthcare journeys. ➡️ myriad.com/genetic-tests/

Today, we announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan. 👉Read more: investor.myriad.com/news-releases/…

☀️🌵 The GeneSight team enjoyed our time in Scottsdale, Arizona, at the American Society of Clinical Psychopharmacology Annual Meeting, where we had the opportunity to present on how pharmacogenomic (PGx) testing—genetic testing that helps guide medication choices—can impact

Today, we announced early access to the FirstGene™ Multiple Prenatal Screen. The company will begin a large study that will simultaneously deliver reports to patients, while generating clinical validity and clinical utility evidence for this transformational new offering.